BETHLEHEM, PA, April 7, 2026
Saladax Biomedical, Inc. has announced a strategic distribution agreement with Thermo Fisher Scientific to expand global access to its advanced therapeutic drug monitoring (TDM) assays, aimed at improving precision dosing and patient outcomes in psychiatry and oncology. This collaboration enables broader availability of rapid, accurate drug level testing, addressing a critical need in managing therapies with high variability and narrow therapeutic windows.
Strategic Partnership Enhances Global Access to TDM
The agreement leverages Thermo Fisher Scientific’s global commercial infrastructure to distribute Saladax’s portfolio of therapeutic drug monitoring assays, significantly increasing accessibility for clinical laboratories worldwide. These assays are designed to monitor widely prescribed medications, including antipsychotic drugs such as clozapine and commonly used chemotherapy agents, where precise dosing is essential for efficacy and safety.
By integrating Saladax’s assays into Thermo Fisher’s distribution network, healthcare providers across multiple regions will gain access to high-quality, clinically validated diagnostic tools that support personalized treatment decisions. This expansion represents a key step in advancing precision medicine, particularly in complex therapeutic areas where patient responses can vary significantly.
Rapid Drug Level Testing Improves Clinical Outcomes
Advertisement
Therapeutic drug monitoring plays a critical role in optimizing treatment regimens, especially for medications with narrow therapeutic ranges and high interpatient variability. Traditional drug monitoring methods often lack the speed required for timely clinical decision-making, limiting their effectiveness in real-world settings.
Saladax’s proprietary assays address this challenge by providing rapid and accurate measurement of drug concentrations, enabling clinicians to adjust dosing in real time, reduce toxicity risks, and improve therapeutic outcomes. This capability is particularly important in oncology and psychiatry, where inappropriate dosing can lead to serious adverse effects or reduced treatment efficacy.
Furthermore, the availability of timely and actionable drug level data allows healthcare providers to make informed decisions that enhance patient safety and treatment success, reinforcing the importance of diagnostics in modern clinical practice.
Seamless Integration into Clinical Laboratory Workflows
A key advantage of Saladax’s technology is its ability to run on existing laboratory instrumentation, eliminating the need for additional capital investment. This ensures that clinical laboratories can easily adopt advanced TDM solutions without significant infrastructure changes, accelerating implementation and scalability.
The compatibility with widely used laboratory systems enables seamless integration into current workflows, allowing laboratories to deliver efficient and cost-effective diagnostic services. This approach supports the broader adoption of therapeutic drug monitoring as a standard component of patient care, particularly in high-risk therapeutic areas.
In addition to clinical applications, Saladax collaborates with pharmaceutical companies to develop companion diagnostics and clinical trial support tools, further strengthening its role in the drug development and lifecycle management ecosystem.
The partnership between Saladax Biomedical and Thermo Fisher Scientific marks a significant advancement in expanding access to precision diagnostic solutions, enabling clinicians to better manage complex therapies through accurate and timely drug level monitoring. By improving dosing precision, reducing toxicity, and enhancing patient outcomes, this collaboration highlights the growing importance of diagnostic innovation in supporting modern healthcare and pharmaceutical treatment strategies.
Source: Saladax Biomedical press release
